Hormonal therapies are effective and well tolerated options for the treatment of acne vulgaris in adolescents with and without endocrine disorders, according to a recent review. They can be used as monotherapy or in conjunction with benzoyl peroxide, topical retinoic acid, or antibiotics. Investigators found:
- There are now 4 different combined oral contraceptive pills that are FDA approved for the treatment of acne since they were introduced in 1960.
- Recent literature has provided more information on the efficacy of different generations of combined oral contraceptive pills, their side-effects, and cancer risks.
- Spironolactone has been gaining wider use among dermatologists in adolescents with endocrine dysfunction.
- New diagnostic guidelines and treatment recommendations have also been suggested.
Nguyen HL, Tollefson MM. Endocrine disorders and hormonal therapy for adolescent acne. Curr Opin Pediatr. 2017;29(4):455-465. doi:10.1097/MOP.0000000000000515.
Hormonal therapies are an effective adjunct for the treatment of acne, not only for those with endocrine disorders but also for patients with a hormonal influence, such as perimenstrual flares. They can be added to treatment regimens that include topical retinoids, antimicrobials, and oral antibiotics. They can also be used as maintenance to help prevent future flares, often in combination with topical retinoids. The efficacy, side effects, and contraindications of oral contraceptive pills (OCPs) have been studied and published in the dermatologic literature. Dermatologists have become more educated about OCPs, which are FDA approved for the treatment of acne, and are thus becoming more comfortable adding this option to their armamentarium. The antiandrogen, spironolactone, has also gained wider use and is very effective for these patients, either in combination with OCPs or alone, especially in those for whom the latter is contraindicated. Hormonal therapies have been a helpful addition for young adult women with endocrinopathies, as well as those who are often bothered by small hormonal flares. As acne often continues into adulthood, hormonal therapies can be beneficial for our patients. —Diane S. Berson, MD, FAAD
This Week's Must Reads
Opioids and the Dermatology Medicare Population, JAMA Dermatology; ePub 2018 Feb 7; Cao, et al
Significant Care Costs Associated with Cellulitis, J Am Acad Dermatol; ePub 2018 Feb 7; St. John, et al
An Analysis of Adherence to Melanoma Treatment , J Clin Aesthet Dermatol; 2017 Dec; Reserva, et al
Underlying Disease Impact on Pyoderma Gangrenosum, J Am Acad Dermatol; ePub 2018 Feb 10; Kaffenberger, et al
FDA Approves Label Update for Cosentyx, Novartis news release; 2018 Feb 8
Must Reads in Acne
New Technology for Acne Evaluations Reliable, JAMA Dermatol; ePub 2017 Dec 20; Singer, et al
Acne Vulgaris: Higher Incidence in Western Nations, Clin Dermatol; 2018 Jan/Feb; Melnik
G2A Regulates Immune Responses to P. Acnes, Ann Dermatol; 2017 Dec; Park, Agak, et al
Study: Acne Vulgaris Affects Quality of Life, J Cosmet Dermatol; 2017 Dec; Gokalp, et al
Factors Affecting Severity of Adult Acne, J Dermatolog Treat; 2017 Dec; Chlebus, et al